Table 4 Multivariate logistic regression analysis of GVHD
Predictor | OR (CI) | p value |
|---|---|---|
Age | 0.998 (0.995–1.002) | 0.66 |
Gender | ||
 Male | 1.205 (0.78–1.851) | 0.41 |
 Female | 1.2014 (0.779–1.852) | 0.55 |
Vaccine Received | ||
 BNT162b2 | 1.365 (0.665–2.8) | 0.51 |
 mRNA-1273 | 1.363 (0.66–2.79) | 0.63 |
Primary diagnosis at HCT, n (%) | ||
 AML | 0.82 (0.33–2.019) | 0.72 |
 ALL | 0.78 (0.315–1.922) | 0.57 |
 Myelodysplastic syndromes/ myeloproliferative neoplasms | 0.712 (0.254–1.992) | 0.92 |
 Myelofibrosis | 0.92 (0.37–2.28) | 0.92 |
 Other | 0.836 (0.35–2.14) | 0.264 |
HCT Donor, n (%) | ||
 MRD | 1.07 (0.381–2.97) | 0.32 |
 MUD | 1.065 (0.38–3.002) | 0.36 |
 MMUD | 0.972 (0.384–3.002) | 0.641 |
 HAPLO | 1.04 (0.371–2.918) | 0.49 |
 MMRD | 0.917 (0.291–2.883) | 0.87 |
 CORD | 2.85 (1.41–5.74) | 0.003 |
Incidence of GvHD relative to transplant date | ||
 0–180 days | 1.64 (0.59–5.891) | 0.9813 |
 180–365 days | 1.27 (0.59–5.907) | 0.9885 |
 > 365 days | 1.33 (0.42–3.118) | 0.965 |
GvHD prior to vaccine | ||
 Yes | 1.02 (0.98–1.07) | 0.166 |
Incidence of GvHD based on systemic immunosuppressant use prior to vaccine | ||
 Yes | 0.99 (0.71–1.38) | 0.967 |